Libo-B's core product Vilisin receives orphan drug designation in Japan

Libo-B announced that the company's core product VELIXIN has been granted orphan drug designation by Japan's Ministry of Health, Labour and Welfare for the treatment of extrapulmonary neuroendocrine carcinoma. This is the third orphan drug designation received by VELIXIN following those from the U.S. Food and Drug Administration and the European Commission, marking a further expansion of VELIXIN's global regulatory recognition footprint into a major Asian market.